Free Trial
NASDAQ:ZBIO

Zenas Biopharma (ZBIO) Stock Price, News & Analysis

Zenas Biopharma logo
$11.24 -0.68 (-5.70%)
As of 04:00 PM Eastern

About Zenas Biopharma Stock (NASDAQ:ZBIO)

Key Stats

Today's Range
$11.23
$12.05
50-Day Range
N/A
52-Week Range
$5.83
$26.25
Volume
111,958 shs
Average Volume
191,221 shs
Market Capitalization
$470.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$40.00
Consensus Rating
Buy

Company Overview

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

Receive ZBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zenas Biopharma and its competitors with MarketBeat's FREE daily newsletter.

ZBIO Stock News Headlines

The Man I Turn to In Times Like This
A storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when publisher Brett Aitken turns to Whitney Tilson—a man CNBC once dubbed “The Prophet.” Tilson just released a new prediction that runs counter to what mainstream finance is telling you.
See More Headlines

ZBIO Stock Analysis - Frequently Asked Questions

Zenas Biopharma's stock was trading at $7.90 at the start of the year. Since then, ZBIO shares have increased by 42.3% and is now trading at $11.24.
View the best growth stocks for 2025 here
.

Zenas Biopharma (ZBIO) raised $225 million in an initial public offering (IPO) on Friday, September 13th 2024. The company issued 13,235,294 shares at $17.00 per share.

Zenas Biopharma's lock-up period expired on Wednesday, March 12th. Zenas Biopharma had issued 13,235,294 shares in its public offering on September 13th. The total size of the offering was $224,999,998 based on an initial share price of $17.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the expiration of the lock-up period.

Zenas Biopharma's top institutional investors include Alps Advisors Inc. (0.07%), Rhumbline Advisers (0.03%) and New York State Common Retirement Fund (0.01%).

Shares of ZBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zenas Biopharma investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Trade Desk (TTD), Advanced Micro Devices (AMD), BioSig Technologies (BSGM), Ford Motor (F) and Genius Sports (GENI).

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ZBIO
Previous Symbol
NASDAQ:ZBIO
Web
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$40.00
High Stock Price Target
$45.00
Low Stock Price Target
$35.00
Potential Upside/Downside
+240.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5 million
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$491.97 million
Optionable
N/A
Beta
N/A
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:ZBIO) was last updated on 5/5/2025 by MarketBeat.com Staff
From Our Partners